Drug Profile
LY 01013
Alternative Names: LPM3480226; LY-01013Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Tablet)
- 18 Dec 2018 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT03844438)
- 07 Sep 2018 China FDA approves clinical trial application for LY 01013 in China before September 2018